Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-15-086743
Filing Date
2015-12-22
Accepted
2015-12-22 20:02:59
Documents
1
Period of Report
2015-12-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6610
  Complete submission text file 0001209191-15-086743.txt   7994
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Issuer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ACLARIS THERAPEUTICS, INC. 101 LINDENWOOD DRIVE, SUITE 400 MALVERN PA 19355
Business Address
Powala Christopher (Reporting) CIK: 0001654301 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37581 | Film No.: 151304049